Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA
CAUMZ targeting survival indications in advanced incurable cancer. Eligible for Fast Track designation and Accelerated Approval regulatory program. 505(b)(2) NDA pathway provides significant cost savings. OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra …